The Food and Drug Administration (FDA) has warned Allergan, the makers of Botox, that the website for its eyelash growth product, Latisse, is misleading because it avoids or downplays risks associated with the product.

The FDA said that Latisse, a prescription only product, either doesn't mention potential side effects including bacterial eye infection, allergic reactions, excess hair growth outside the intended treatment area, and permanent changes in iris and eyelid pigmentation, or presents them in small text that is much less prominent than statements about the product's effectiveness. In some cases, pages on the Web site leaves out information that is included in Latisse packaging.

The FDA approved Latisse as an eyelash growth product last December.The active ingredient, bimatoprost, is a drug that is used for the treatment for glaucoma. Some users of rival over the counter eyelash growth products such as LiLash, which also use a glaucoma drug, have told Truth In Aging that they have suffered side effects such hair growing on their cheeks.

I just checked out the Latisse site and it seems to have responded rapidly to the FDA's complaints. There is a clearly positioned 'about safety' tab on the home page and the potential side effects, including permanent change of eye color, are set out in full.